Friday, June 06, 2025 8:43:04 AM
Hi PGSD - here is an AI summary of this patent application -
Key Findings from Patent Application WO2025106534
Title: Processing Instrument for Cellular Therapy Manufacturing
The patent application WO2025106534 introduces an advanced system designed to automate and optimize the production of genetically modified immune cells, such as CAR T cells. This innovation aims to enhance efficiency, consistency, and scalability in cell therapy manufacturing.
Key Innovations
• Fully Enclosed Automated System: Integrates activation, transduction, expansion, concentration, and harvesting within a closed environment to minimize contamination risks.
• Integrated Monitoring and Control: Equipped with sensors for temperature, pH, glucose, oxygen, and CO2, enabling real-time adjustments.
• Enhanced Cell Yields: Capable of producing up to 2 billion viable genetically modified immune cells, surpassing yields from flexible culture bags.
• Versatile Transduction Methods: Supports viral vectors and electroporation for flexible gene delivery.
• Accessory Cell Integration: Includes accessory cells like monocytes to support T cell activation and expansion.
• Optimized Culture Conditions: Maintains specific cell densities and confluency to promote optimal cell phenotypes.
• Scalable and Modular Design: Modular architecture allows scalability and adaptation to various production scales.
This patent represents a significant advancement in the field of cellular therapy manufacturing, offering a comprehensive solution to challenges in scalability, consistency, and efficiency.
SF
Key Findings from Patent Application WO2025106534
Title: Processing Instrument for Cellular Therapy Manufacturing
The patent application WO2025106534 introduces an advanced system designed to automate and optimize the production of genetically modified immune cells, such as CAR T cells. This innovation aims to enhance efficiency, consistency, and scalability in cell therapy manufacturing.
Key Innovations
• Fully Enclosed Automated System: Integrates activation, transduction, expansion, concentration, and harvesting within a closed environment to minimize contamination risks.
• Integrated Monitoring and Control: Equipped with sensors for temperature, pH, glucose, oxygen, and CO2, enabling real-time adjustments.
• Enhanced Cell Yields: Capable of producing up to 2 billion viable genetically modified immune cells, surpassing yields from flexible culture bags.
• Versatile Transduction Methods: Supports viral vectors and electroporation for flexible gene delivery.
• Accessory Cell Integration: Includes accessory cells like monocytes to support T cell activation and expansion.
• Optimized Culture Conditions: Maintains specific cell densities and confluency to promote optimal cell phenotypes.
• Scalable and Modular Design: Modular architecture allows scalability and adaptation to various production scales.
This patent represents a significant advancement in the field of cellular therapy manufacturing, offering a comprehensive solution to challenges in scalability, consistency, and efficiency.
SF
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
